Abstract Details

Title Depression of AD: An Evidence-Based Epidemiological Systematic Review on Prevalence and Symptoms

Topic Behavioral Neurology

Presentation(s) P05 - (-)

Poster/Presentation
Number 116

Objective

Background BACKGROUND: The NIMH-Provisional diagnostic criteria for depression of AD (PDC-dAD) were developed specifically for the diagnosis of depression in Alzheimer's Disease (AD). They differ from the DSM criteria for Major Depressive Disorder (MDD) because a) the severity of signs and symptoms of dAD is lower; b) it includes additional symptoms (irritability, social isolation and withdrawal); c) symptoms are phrased to avoid confounding with diminished language/cognitive abilities in AD. A decade after their inception there still is inconsistent use of assessment methods for studying depression in AD including the PDC-dAD, DSM, ICD and specific depression scales. Here we conduct an evidence-based examination of the prevalence estimates (PE) of depression in AD by PDC-dAD and other diagnostic approaches.

Design/Methods DESIGN/METHODS: We performed a systematic search of the electronic literature and included all studies that report on the prevalence of depression of AD by PDC-dAD and at least by one other diagnostic or assessment approach.

Results RESULTS: Five observational studies satisfied the inclusion criteria. PE by PDC-dAD ranged from 27.4 to 53.6% (median of 44%). PE by DSM-MDD ranged from 9.3 to 34.8% (median 14%). In 4 studies, the PE by ICD were 4.9 to 47.3% (median 32.4%). In 3 studies, the PE by the Neuropsychiatric Inventory (depression or dysphoria [NPI-Q] endorsed) ranged from 43.7% to 54% (median 50%). Other measures were inconsistently used and reported PE of 9.8 to 49.7%.

Conclusions CONCLUSIONS: The prevalence of depression in AD varies widely as a function of diagnostic approach, with higher prevalence rates associated with PDC-dAD than DSM or ICD. This raises important questions for future research about phenotype of depression in AD, particularly because neuropsychiatric symptoms are included in the McKhann 2011 NIA-AA diagnostic framework for all-cause dementia.

Authors/Disclosures
Amir A. Sepehry (University of British Columbia) PRESENTER	No disclosure on file
	No disclosure on file
	No disclosure on file
Ging-Yuek R. Hsiung, MD, FAAN (University of British Columbia)	Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eisai. Dr. Hsiung has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Eli Lilly. The institution of Dr. Hsiung has received research support from CIHR. The institution of Dr. Hsiung has received research support from NIH. The institution of Dr. Hsiung has received research support from Eli Lilly. The institution of Dr. Hsiung has received research support from Biogen.
	No disclosure on file
Philip E. Lee, MD	No disclosure on file
John W. Day, MD, PhD (Stanford University School of Medicine)	Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis Gene Therapy. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Biogen. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche/Genentech. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Sarepta. Dr. Day has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Avidity. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PepGen. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Epirium Bio. Dr. Day has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Solid Biosciences. Dr. Day has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Muscular Dystrophy Association. The institution of Dr. Day has received research support from Astellas Pharma. The institution of Dr. Day has received research support from Novartis Gene Therapy. The institution of Dr. Day has received research support from Biogen. The institution of Dr. Day has received research support from Roche/Genentech. The institution of Dr. Day has received research support from Sanofi/Genzyme. The institution of Dr. Day has received research support from Sarepta. The institution of Dr. Day has received research support from Scholar Rock. The institution of Dr. Day has received research support from AMO Pharma. The institution of Dr. Day has received research support from AnnJi. Dr. Day has received research support from CureSMA. The institution of Dr. Day has received research support from Muscular Dystrophy Association. The institution of Dr. Day has received research support from Ionis Pharmaceuticals. The institution of Dr. Day has received research support from NMD Pharma. The institution of Dr. Day has received research support from SMA Foundation. Dr. Day has received intellectual property interests from a discovery or technology relating to health care.
Claudia Jacova	No disclosure on file

��ɫ��

��ɫ��